U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.	SERIAL NO.
16137	10/723,635

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

APPLICANT: MICHAEL A. STURBA ET AL.

FILING DATE	GROUP
NOVEMBER 26, 2003	

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
		4,817,905	04/04/1989	Rondone			
		4,965,946	10/30/1990	Hegedus et al.			
		5,458,242	10/17/1995	Baka et al.			
		5,573,110	11/12/1996	Nguyen			
		5,950,341	09/14/1999	Cross			
		5,993,928	11/30/1999	Popat			
		5,996,130	12/07/1999	Verhines			
		6,220,555	04/24/2001	Chase			
		6,294,237	09/25/2001	Popat			
		2002/0158116	10/31/2002	Shair			
		6,631,839	10/14/2003	Shair			

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES	TRANSLATION NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

C:\2157\16137.BFX

Compounds known to be proteasome or NF-κB inhibitors include:

Proteasome Inhibitors	
PSI	N-carbobenzoyl-Ile-Glu-(OtBu)-Ala-Leu-CHO
MG-132	N-carbobenzoyl-Leu-Leu-Leu-CHO
MG-115	N-carbobenzoyl-Leu-Leu-Nva-CHO
MG-101 or Calpain Inh I	N-Acetyl-Leu-Leu-norLeu-CHO
ALLM	N-Acetyl-Leu-Leu-Met-CHO
	N-carbobenzoyl-Gly-Pro-Phe-Leu-CHO (SEQ ID NO:1)
	N-carbobenzoyl-Gly-Pro-Ala-Phe-CHO (SEQ ID NO:2)
	N-carbobenzoyl-Leu-Leu-Phe-CHO
	N-carbobenzoyl-Leu-Ala-Leu-CHO
Gliotoxin	
SN50	NLS of NF-κB MW 2781
Bay 11-7082	
Capsaicin	
PDTC	
ALLN	 N-Acetyl-Leu-Leu-Nle-CHO

Please replace the paragraph beginning on page 37, line 4, with the following amended paragraph:

An assay to test the effect of compounds on the 20S thermophila proteasome activity was employed. Purified 20S thermophila proteasomes and the fluorogenic peptide substrate Suc-Leu-Leu-Val-Tyr-AMC (SEQ ID NO:3) are available from CalBiochem, San Diego, CA. Briefly, serial dilutions of the inhibitor to be tested were mixed with proteasome solution at a concentration of proteasome of 0.01 mg/ml. After 30 min incubation at 37°C, substrate solution at a final concentration of 25-30 μg/ml was added and the mixture incubated at 37°C and then read at 15 min, 30 min, and 60 min in a Fluoroscan instrument. The percentage diminution in fluorescence in the presence as compared to the absence of inhibitor is then calculated.